Scholar Rock Holding Corp (SRRK) Stock Analysis
Verdict: WATCH (do not buy)
Apitegromab's SMA commercial launch underpins long-term growth, but $300M annual cash burn creates near-term dilution risk.
Investment score: 40/100
Analysis as of
Is Scholar Rock Holding Corp stock worth reviewing? The TradeMates thesis
Scholar Rock is a clinical-stage biotech transitioning toward commercialization with lead asset Apitegromab. While Phase 3 trial success in SMA and consensus revenue projections ($140M in 2027, $650M in 2029) support valuation upside, heavy annual cash burn (-$300.6M in 2025) and insider selling signal near-term dilution risk.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 40/100 (weight 15%)
- Technical Momentum: 50/100 (weight 15%)
- Earnings Quality: 30/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 65/100 (weight 10%)
- Risk-Adjusted Return: 45/100 (weight 15%)
Scholar Rock Holding Corp opportunities and risks
What speaks for SRRK
- Apitegromab Phase 3 SMA trial completion sets up potential commercial launch by 2027
What speaks against SRRK
- Severe cash burn rate creates immediate financing and dilution risk
Frequently asked questions about Scholar Rock Holding Corp (SRRK)
Is SRRK stock a good investment?
The TradeMates model rates Scholar Rock Holding Corp as WATCH (do not buy) with an investment score of 40/100. Scholar Rock is a clinical-stage biotech transitioning toward commercialization with lead asset Apitegromab. While Phase 3 trial success in SMA and consensus revenue projections ($140M in 2027, $650M in 2029) support valuation upside, heavy annual cash burn (-$300.6M in 2025) and insider selling signal near-term dilution risk. This is algorithmic model output, not personal investment advice.
Is SRRK stock a buy?
The TradeMates model verdict for SRRK is WATCH (do not buy) with an investment score of 40/100. Treat this as a model signal to review, not a personal buy recommendation.